Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
Author:
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference39 articles.
1. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study;Yang;Lancet Respir Med.,2020
2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis;Tan;Lung Cancer.,2020
3. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia;Zhou;Signal Transduct Target Ther.,2020
4. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis;Addeo;Front Oncol.,2019
5. Poor-performance status assessment of patients with non-small cell lung cancer remains vague and blurred in the immunotherapy era;Friedlaender;Curr Oncol Rep.,2019
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Management of stage III non-small-cell lung cancer: rays of hope;Exploration of Targeted Anti-tumor Therapy;2024-02-19
2. Organizational Impact of Immunotherapies in Advanced Cancers in France;JCO Global Oncology;2023-08
3. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer;JAMA Oncology;2023-08-01
4. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis;Frontiers in Immunology;2023-07-13
5. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control;Journal of Cancer Research and Clinical Oncology;2023-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3